It has long been suggested that the import of nuclease colicins requires protein processing, however it had never been formally demonstrated. Here we show that two RNase colicins E3 and D, which appropriate two different translocation machineries to cross the outer membrane (BtuB/Tol and FepA/TonB, respectively), undergo a processing step inside the cell which is essential for their killing action. We have detected the presence of the C-terminal catalytic domains of these colicins in the cytoplasm of target bacteria. The same processed forms were identified in both colicin-sensitive cells or in cell immune to the colicin due to the expression of the cognate immunity protein. We demonstrate that the inner-membrane protease FtsH is necessary for the processing of colicins D and E3 during their import. We also show that the signal-peptidase LepB interacts directly with the central domain of colicin D in vitro and that it is a specific, but not catalytic requirement for the in vivo processing of colicin D. The interaction of colicin D with LepB may ensure a stable association with the inner membrane that in turn allows the colicin recognition by FtsH. We have also shown that the outer membrane protease OmpT is responsible for alternative and distinct endoproteolytic cleavages of colicins D and E3 in vitro, presumably reflecting its known role in the bacterial defence against antimicrobial peptides. Even though the OmpT-catalysed in vitro cleavage also liberates the catalytic domain from colicins D and E3, it is not involved in the processing of nuclease colicins during their import into the cytoplasm.
for cell killing) and it is also involved in formation of the colicin D-ImmD protein complex (7) . The passage of colicin D through the outer membrane is dependent on the proton motive force of the cytoplasmic membrane, transduced by the TonB/ExbB-D system (8, 9) .
During the import process, when E-type nuclease colicin-Imm complexes bind to the cell surface receptor BtuB, their Imm protein dissociates from the bound colicin and is released into the external medium (10, 11) . The binding per se of the complex is however not enough to liberate the Imm protein. The dissociation of colicins E9-and E2-Imm complexes requires the unfolding of the colicin, as it contacts the energy-transducing Tol system in the periplasm (12, 13) .
In order to transfer the cytotoxic domain of the colicin molecule across the inner membrane into the cytoplasm, nuclease colicins need to parasitize more of the cell's functions than the pore-forming colicins. The DNase domains of colicins E9 and E2 exhibited nonvoltage-gated channel-forming activity in planar lipid bilayers, which involved changes in their conformation (14) . Such channels, unlike those formed by pore-forming colicins, are not directly responsible for cell killing, but may allow "self-propulsion" of the toxic domains into cytoplasm, driven by an electrostatic association of the DNase domain of colicin E9 with the inner membrane (15) . Although such an association between the RNase colicin E3 and anionic phospholipid surfaces has been reported, no RNase colicin has been found to exhibit any channel forming activity (16) .
Using cell extracts the in vitro cleavage of full-size colicin D and more recently of the DNase colicin E7 was observed at the boundary of the C-terminal killing and central domains (17) (18) (19) . The inner-membrane signal peptidase LepB was shown to be essential for cell killing by colicin D and also for the cleavage of colicin D in vitro, in the presence of a cell extract. We and others proposed that proteolytic processing may be a common step in cell killing by nuclease type colicins and that it should occur prior to or concomitant with the translocation of their C-terminal catalytic domain through the inner membrane (17, (19) (20) (21) .
OmpT is a member of the family of outermembrane endopeptidases (omptins) and plays a role in the virulence of a variety of pathogenic Gram-negative bacteria (22) . Moreover, in agreement with earlier observations OmpT was shown to cleave several receptor-bound colicins and thus, improves the survival of target bacteria exposed to colicins or other antimicrobial peptides (23) (24) (25) .
In this work, we have identified the in vivo processed forms of both RNase colicins D and E3, as the final colicin forms present in the cytoplasm of colicin-treated bacteria. The endoproteolytic cleavage was shown to require the inner-membrane protease FtsH, which is known to be required for cytotoxicity of all nuclease colicins (26) . Additionally the signalpeptidase LepB is specifically required for the processing and/or translocation of colicin D across the inner membrane. The in vitro cleavage of colicin D and E3 requires the outer membrane protease OmpT. However, OmpT is not required for the import and toxicity of colicins.
Experimental Procedures
Bacterial strains and plasmids-E. coli K12 strains C600 and JM101 were used as wildtype strains. DH5 was used as the host strain for cloning and mutagenesis. All other strains and plasmids used or constructed are listed in Table 1 .
Purification of colicins-Unlabelled colicin D or labelled in vivo with [
35 S]Met (1000 Ci/mmol, Amersham), in complex with its immunity protein (ImmD) was purified from an E. coli strain carrying pJF129 as previously described (17, 27) . Colicin D was separated from its ImmD by gel filtration in the presence of 9 M urea (Superose 12HR column, Pharmacia) and refolded by dialysis against 20 mM Tris/HCl, pH 8.0.
Colicin E3-ImmE3 complex was purified from an E. coli strain carrying pKSJ28 and then dissociated by two chromatographic steps on a Mono S column (Pharmacia) without and with 6 M urea, respectively according to de Zamaroczy et al. 2001 .
Alternatively, colicin D in complex with the ImmD protein carrying a C-terminal 6His tag (colicin D-ImmD(Ct-6His) was produced from BL21(DE3) cells carrying the plasmid pColDI in LB medium with ampicillin. At A 600 =0.5 the expression of the colicin operon was induced by IPTG (1 mM) and the incubation was continued for 3h at 37 °C. After centrifugation the cells were resuspended in 20 ml of loading buffer (20 mM Tris, pH 8.0, 0.5 M NaCl and 200 g DNase) and then broken by one passage through a French pressure cell. The supernatant was loaded onto a 1 ml Ni-NTA resin column (His-select Nickel affinity gel; SIGMA), previously equilibrated with the loading buffer, washed with the same buffer and the His-tagged colicin D-ImmD complex was then eluted with 150 mM imidazole. After denaturating the complex in 9 M urea, the Histagged ImmD was retained by two passages over Ni-NTA column. Colicin D freed of ImmD present in the "flow through" was concentrated (ultrafiltration Amicon Ultra-4 10K NMWL; Millipore) after dialysis. The same protocol was used to produce colicin E3-ImmE3(Ct-6His) from plasmid pColE3I. Purification of the 12.4 kDa colicin D catalytic domain in complex with ImmD-The cloned catalytic domain corresponds to amino acids M590-L697 from the C-terminal part of colicin D. Met590 had been chosen as initiating amino acid because it corresponded to a spontaneous break in the protein, which occurred during the crystallisation of the colicin D in complex with ImmD (27). The catalytic domain in interaction with the 10.9 kDa ImmD(Ct-6His) was expressed from BL21(DE3) carrying the plasmid pCDM590 and purified as described above. The catalytic domain, used for antiserum production, although separated from its ImmD partner by 9 After an incubation of 1 h at 37 °C with LepB (1g/ml) and successive washing steps, the binding of LepB to colicins was analyzed by an anti-LepB antiserum and ECL. In vitro analysis of colicin cleavage-Extracts of E. coli periplasmic proteins were prepared by a classical osmotic shock procedure, adapted from the QIAexpressionist protocol (Fourth  edition,  QIAGEN,  2000) . Alternatively, cell fractionation was performed using a spheroplast producing protocol, based on lysozyme treatment of the cells (30). Aliquots of periplasmic extract were stored at -20 °C, in 20 mM Na phosphate (pH 6.5), 5 mM MgSO 4 . Periplasmic-protein extracts with or without addition of purified OmpT (with LPS, 0.4 g (31)) and/or LepB (1.5 g) or SipS, were incubated for 1h at 37 °C, in 20 mM Na phosphate, 5 mM MgSO 4 (pH 7.0), with unlabelled or [
35 S]Met-labelled colicin (4 and 1.5 g, respectively). Full-size (FS) and cleaved colicin forms (LC and SC) were precipitated with acetone, then separated by SDS-PAGE, and the proteins were detected by Coomassie blue staining or phosphorimagery (GE Healthcare Typhoon), respectively. The periplasmic extracts obtained by the two methods were used in parallel for the colicincleavage tests and gave the same results in three repeat experiments. Polymixin B is known to form a complex with lipopolysaccharides (LPS), which are necessary for the activity of OmpT (32). It was added (3 g/ml) to the reaction mixture to test the OmpT dependence of the in vitro colicin cleavage.
Identification by "fishing" of the in vivo processed colicin peptides from colicin D or colicin E3 treated target cells-50 ml cultures of wild-type or mutant E. coli strains, carrying the plasmid pImmD, were grown in LB medium to OD 600 = 0.4, at 37°C, then induced for 1 hour with 1 mM IPTG, to express the plasmid encoded His-tagged colicin D immunity protein and with 0.05 mM 2,2'-dipyridyl. 1 mg of colicin D-ImmD complex was added to the cultures for 1-3 hours. The cells were harvested, washed twice, resuspended in 10 ml of 20 mM Na-phosphate, 150 mM NaCl, pH 7.0, and treated with proteinase K at 100 g/ml for 1 hour at 37 °C After four additional washings the colicin Dand proteinase K-treated cells were resuspended in 2 ml buffer (Tris 20 mM, 0.5 M NaCl pH 7.5) with a protease inhibitor complex (Complete EDTA-free; Roche) and then disrupted by sonication. The soluble fraction recovered after centrifugation was then loaded onto a Ni-NTA affinity column. The bound His-tagged ImmD, carrying any attached colicin molecules which have been "fished" from the cytoplasm, was eluted with 300 mM imidazole, dialysed and concentrated (ultrafiltration Amicon Ultracel 3K; Millipore). The processed colicin D peptide (ColD PF) (recovered from about 10 ml of the initial cell culture) was separated from the His-tagged ImmD on 15 % SDS PAGE, identified by western blot analysis, using an antiserum to the colicin D catalytic-domain, to the immunity protein or to the full-size colicin D and detected by ECL chemiluminescence (BIO-RAD, Immun-Star) associated with a CCD camera (BIO-RAD ChemiDoc XR System+). A similar protocol to that used for colicin D, but without 2,2'-dipyridyl, was used to look for processing of colicin E3. Wild-type or mutant strains carrying plasmid pImmE3, encoding the His-tagged colicin E3 immunity protein, were grown in LB or minimal medium (IPTG) and treated with colicin E3-ImmE3 for 1-2 hours. Proteins bound to the ImmE3-6His were purified by Ni-NTA chromatography and Western blot analysis was performed with an anti-colicin E3 antiserum. The His-tagged ImmE3 was detected from the bottom part of the same SDS-PAGE blot by an anti-6His antiserum. Direct immuno detection of processed colicin D and colicin E3 peptides in the S100 cytoplasmic fraction of colicin sensitive target cells-The direct immuno-detection of the in vivo processed product required an increased colicin D import into target cells and further purification to remove other cytoplasmic proteins. A 50 ml culture of strain AD202 at OD 600 = 0.3 and 37 °C was induced by 0.05 mM 2,2'-dipyridyl. At OD 600 = 0.8, 0.7 -2 mg colicin D-ImmD was added to the cells for 1 -2 h. After harvesting the cells were treated with proteinase K, washed and the cytoplasmic fraction was prepared as described above. Ribosomal proteins were eliminated from cytoplasmic extracts by microultracentrifugation at 100 S (Beckman rotor TLA 100.2) to give an S100 fraction. To increase the threshold of detection of the processed colicin D form, S100 fractions were enriched for lower-MW proteins. Thus, the S100 fraction was precipitated with acetone. Proteins were resuspended in 350 l of 20 mM pH 7.0 Na-phosphate buffer and separated by FPLC monitored gel filtration (Superdex 75 GL 10/300). Fractions containing proteins with molecular weights lower than 35 kDa were pooled and precipitated by acetone. The concentrated and selectively enriched cytoplasmic proteins, were separated on 15 % SDS-PAGE, and analysed by Western blotting as described above.
In the case of colicin E3, S100 fractions, prepared from cells grown in LB or in minimal medium (to enhance the expression of BtuB receptor) and treated by 2 -4 mg colicin E3-ImmE3 for 0.25 -2 h, were separated on 15 % SDS-PAGE and directly analysed by Western blotting with anti-colicin E3 antiserum. When necessary, ECL detected proteins were quantified by ImageLab software (BIO-RAD).
RESULTS
In vitro cleavage of colicin D in periplasmic extracts. We previously showed that only when a crude extract of the colicin D resistant strain A38 carrying the lepB (N274K) mutation was supplemented with purified LepB, it was capable of the endoproteolytic cleavage of full-size colicin D molecules. But LepB alone was not able to cleave colicin D (17) (Figure 1C, lane 4) . We sought therefore to identify an additional component that might be required with LepB for colicin D cleavage. We chose to focus our investigation on periplasmic protein extracts, since the active site of the inner membrane protein LepB is oriented towards the periplasmic space (33). When LepB was added to the periplasmic extracts, prepared from the lepB mutant, about 50 (+/-7) % of the full size (FS) 75-kDa colicin D (free of its immunity protein) was found to be cleaved. A 65 kDa large-cleaved (LC) form ( Figure 1A , lane 2) and an about 11 kDa smallcleaved (SC) form (data not shown) were visualised by SDS PAGE. The N-terminal amino acid sequence of the SC peptide was determined to be (K 608 )YKHAGDFGISD (Figure 2A) . The in-vitro cleavage site is located between two lysines residues at positions 607 and 608, so that cleavage liberates a C-terminal peptide of 10.5 kDa, which corresponds in size to the previously defined minimal tRNase domain of colicin D (17) .
The outer-membrane OmpT is the protease necessary for the colicin D cleavage in vitro. The cleavage site, between two basic residues, satisfies the amino acid requirement for cleavage by the outer-membrane OmpT protease (34). In the presence of LepB, about 45 (+/-7) % colicin D was cleaved in vitro with purified OmpT-(LPS) ( Figure 1C , lane 1). However only a marginal cleavage of colicin D (< 5 %) was detected with OmpT alone (data not shown). We checked that colicin D cleavage is completely inhibited when polymixin B was added to the reaction mixture ( Figure 1A , lane 3). Polymixin B is known to form a complex with lipopolysaccharides (LPS), which are necessary for the activity of OmpT (32). The N-terminal sequence of the SC form, liberated by the purified LepB and OmpT together ( Figure 1B) showed that it corresponds to exactly the same cleavage site as observed with LepB and the periplasmic extract ( Figure 2A ). We confirmed that OmpT protease was responsible for the in vitro cleavage by preparing periplasmic extracts from ompT mutant strains (AD202 and C600ompT). These periplasmic extracts supplemented with LepB were not able to cleave colicin D. But the endoproteolytic cleavage of colicin D was efficiently restored using extracts from the same strains overproducing wild-type OmpT from plasmid pML19 if supplemented with LepB ( Figure  1D , lanes 2, 3).
LepB catalytic activity is not involved in colicin D cleavage by OmpT. To further analyse the function of the LepB peptidase we studied in vitro the cleavage of colicin D by
OmpT in the presence of purified mutant-LepB protein (K145A). This mutation affects an essential residue in the active site of LepB without causing significant conformational change. Thus, it prevents both in vitro and in vivo the processing of the natural substrates of LepB (35). Despite the loss of its normal catalytic function, LepB (K145A) was able to promote the in vitro cleavage of colicin D by OmpT ( Figure 1C lane 2) . This indicates that the catalytic activity of LepB is not required, for colicin D cleavage in vitro. We also showed that the LepB orthologue SipS of Bacillus amyloliquefaciens could replace LepB for the cleavage of colicin D ( Figure S1 ) and we observed that the SipS protein from plasmid pGDL81 restored efficiently the sensitivity of the A38 lepB mutant to colicin D.
LepB interacts with colicin D in vitro. Figure 3C -F) the same amount of wild-type LepB was included (lanes C) and used as a standard to validate the quantitative comparison of LepB specific bands from these blots. We checked that the variations in the interaction are not due to a difference in the affinity of the anti-LepB antiserum for the LepB-mutant proteins. As shown in Figure 4G this antiserum has equal affinity for the recognition of wild-type and each mutant LepB protein. Since the wild-type and non-catalytic LepB protein exhibited a similar capacity to form a complex in vitro with the central domain of colicin D, we verified that the plasmid pRD8(K145A), expressing the LepB-mutant protein K145A, complemented the lepB(N274K) mutant strain A38 for colicin D sensitivity, as well as the wild-type LepB, expressed by plasmid pRD8 (data not shown). These experiments indicate that colicin D import requires LepB, but not its catalytic activity and presumably necessitates a direct interaction of the toxin with LepB in the periplasm.
The in vitro-demonstrated cleavage of RNase colicins by OmpT has no role in their in vivo processing. We investigated if other colicins were subject to OmpT cleavage in vitro by examining the RNase colicin E3, which parasitizes the Tol system for its import. Using [
35 S]Met-labelled colicin E3, free of its immunity protein, two large-cleaved (LC) fragments, 47 and 45 kDa, ( Figure 2B ) were obtained from the 58 kDa full-size (FS) colicin, in the presence of periplasmic extracts prepared from either the wild-type or lepB (A38) mutant strains ( Figure 4A , lanes 2, 4). As expected, LepB is not a requirement for the in vitro cleavage of colicin E3 (20) . Purified OmpT restored the cleavage of colicin E3, when the assay was performed in an extract from an OmpT-deficient strain ( Figure 4A,  lanes 5, 7) . However, only the shorter, 45 kDa LC form was detected with purified OmpT, even in the absence of periplasmic extract ( Figure 4A, lanes 3, 7) . This suggests that the amount of OmpT is limiting in the periplasmic extracts so that partial cleavage at one or other of two sites in colicin E3 is observed ( Figure  2B ). When purified OmpT is added in excess both sites are fully cleaved and only the shorter LC form is detected ( Figure 4A ). The OmpT protease is located in the outer membrane and oriented so that its active site is extracellular (36). The limited OmpT activity we have observed in periplasmic extracts may be either the consequence of its release from the inner membrane into the periplasmic space during its passage to the outer membrane (37) or due to some contamination, derived from the methods used for the preparation of the periplasmic extracts. Mass spectrometry analysis of the 47 kDa LC form localized an OmpT-dependent cleavage site between residues R454 and K455, located inside the short linker peptide (38) ( Figure 2B ). The peptide motif (R 432 )KKKEDKK(R 440 ) carries several other consensus OmpT-cleavage sites, which are presumably responsible for producing the 45 kDa LC form. Two short fragments (13 and 11 kDa SC forms) were detected by Western blotting with anti-colicin E3 antiserum and correspond to the C-terminal nuclease domain of colicin E3, corresponding to the 45 and 47 kDa LC products ( Figures 2B and S2) .
We examined the sensitivity of OmpTdeficient strains towards nuclease colicins. ompT strains (AD202, C600ompT and the E. coli B BL21) were all shown to be fully sensitive to colicins D and E3, as observed by the cytotoxicity test ( Figure 4D ), and to DNase colicin E2 (25) . Therefore, OmpT is not necessary for colicin import and toxicity. We also examined the sensitivity of wild-type and OmpT overexpressing strains to colicins D and E3. The toxicity of these RNase colicins in complex with their cognate immunity proteins, as judged by the growth-inhibition test, diminished by one order of magnitude, when OmpT was overexpressed from a high copynumber plasmid pML19. More importantly, colicin E3, free of its Imm protein, almost completely lost its toxicity against wild-type cells. In the case of colicin D freed of its Imm protein, wild-type cells were sensitive, while OmpT-overexpressing cells were resistant ( Figure 4D) . Thus, the Imm proteins appear to efficiently prevent the bacterial defense system mediated by OmpT from functioning, as was previously shown in the case of colicin E2 (25) . Moreover, the Imm proteins become essential for the killing action of these colicins when the OmpT activity of target cells increases.
Identification of a processed form of colicin D in the cytoplasm of target cells by "ligand fishing" with the ImmD protein.
To verify that processing of nuclease colicins did occur and was required for import and toxicity, we set up an in vivo "fishing" assay to detect a processed form of colicin D in the cytoplasm based on its high affinity interaction with its immunity protein (27). Wild-type or OmpTdeficient bacteria expressing plasmid-born Histagged ImmD protein were treated with purified colicin D-ImmD complex. To enhance the penetration of colicin D into the periplasm, target cells were previously treated with 2,2'-dipyridyl, which increases the expression of FepA and TonB (39), necessary for colicin D translocation across the outer membrane. Any colicin D fragments, complexed with the ImmD-6His protein and "fished" from the cytoplasm, were analysed by Western blotting with anti-colicin-D-catalytic-domain antiserum. The same two bands were detected in both wild-type and OmpT-deficient strains ( Figure 5A lanes 1, 3) . Since this antiserum cross-reacts with ImmD (see Experimental Procedures) the band with lower mass corresponds to ImmD-6His (10.9 kDa), as verified by a specific reaction with anti-ImmD antiserum (data not shown). The slightly heavier band corresponds to the in vivo processed colicin D form (called "PF" to distinguish it from the small in vitro cleaved (SC) form; Figure 2A ). The in vivo processed form is absent from the cytoplasm of control cells, not treated with colicin D (Figures 5A lanes 5-8, 10 ) or of cells treated with colicin D, but not induced with dipyridyl (data not shown). As expected no processed colicin D form was found in tonB-or fepA-inactivated mutants, in which translocation of colicin D across the outer membrane is blocked ( Figure  5A lanes 2, 4) . In particular, there is no colicin D processing in the tonB mutant strain D1 (R158S), which completely prevents the import of colicin D, but remains competent for FepAdependent iron uptake ( Figure 5A lane 11) (40).
Significantly, colicin D processing was abolished in the lepB(N274K) mutant strain A38, which specifically prevents colicin D toxicity. This processing defect was complemented by the plasmid pLEPB(wt) ( Figure 5B lanes 1, 2) . This demonstrates that LepB does indeed have a specific functional role in the processing of colicin D.
The essential inner membrane FtsH protease was previously observed to be required for sensitivity to nuclease colicins (26) . As in the case of the lepB mutant, no processed colicin D was detected in an ftsHinactivated mutant strain (in a lethalitysuppressed background of strain AR3291; Table 1 ), but the processing was fully restored, when the plasmid pFTSH was introduced ( Figure 5B lanes 3, 4) . This result raised the possibility that FtsH may be the translocator of colicin D across the inner membrane. By hijacking FtsH function, colicin D could be processed in the inner membrane so releasing the catalytic domain, which is able to reach its cytoplasmic target. In this scenario LepB, in turn could be essential to interact with colicin D and so may facilitate its access to the FtsH active site.
Direct immuno-detection of the processed form of colicin D in the S100 cytoplasmic fraction of sensitive cells exposed to colicin D. In the "ligand-fishing" experiment, the ImmD expressing cells are protected against cell killing by the colicin D treatment, but we could not exclude the possibility that the PF, may be a consequence of proteolytic degradation, destined to rid the cytoplasm of the inactivecolicin D-ImmD complexes formed during the import. Thus, we attempted to directly detect the processed form in the cytoplasm after a shorter (0.5 -1.5 h) treatment with colicin D. The C-terminal PF of colicin D, either detected directly in the S100 fraction of colicin Dtreated cells ( Figure 5C lanes 1, 2) or captured by "fishing" technique ( Figure 5C (17) .
Identification of the processed form of colicin E3 in the cytoplasm of target cells. We wondered if proteolytic processing was a characteristic of all RNase colicins and so looked for the processed form of colicin E3 by direct immuno-detection in the cytoplasm. The same unique peptide, with a MW of about 15 kDa was detected by an anti-colicin E3 antiserum from the S100 fractions of ompTinactivated ( Figure 6A lanes 1, 2) and wildtype strains ( Figure 6B lane 8) , confirming that OmpT is not involved in the in vivo processing of colicin E3. The former experiments were performed in minimal medium, in which the low level of vitamin B12 was expected to increase BtuB-receptor expression. The same peptide, with 3-fold lower intensity, was present in colicin-E3 treated cells grown in LB (Figure 6A lane 6) . In both media, the processed form of colicin E3 (PF) was detected efficiently, after only 15 minutes of treatment of cells with colicin E3-ImmE3 ( Figure 6C lane 4). Detection of a similar level of PF with colicin D in 15 min necessitated about 8-times more S100 extract (data not shown). The rapidity of the appearance of the PF is consistent with our observation ( Figure 5C ) that it was generated during the translocation step (allowing the entry of the catalytic domain into the cytoplasm through the inner membrane), rather than by some proteolytic degradation of longer colicin molecules which have accumulated in the cytoplasm after their translocation.
Quantification of the time-course of colicin E3 PF appearance ( Figure 6C) showed that it increased four-fold during the first hour of treatment with colicin.
No processed forms were detected in the cytoplasm of tolB-or btuB-inactivated mutant strains ( Figure 6A lane 5 and Figure 6B lane 3), which is in agreement with the involvement of the BtuB receptor and the Tol system in the translocation of colicin E3 across the outer membrane. In addition, we showed that FtsH deficience, as in the case of colicin D, prevented detection of the processed form of colicin E3 (Figure 6B lane 1) . However, unlike colicin D, colicin E3 toxicity is not eliminated by the lepB (N274K) mutation (20) . It was thus unexpected to observe lower amounts of the colicin E3 processed form in extracts from the A38 strain than from the wild-type ( Figure 6B  lanes 7-8) . The amount of processed colicin E3 was restored in extracts from the A38 strain carrying the pLEPB(wt) plasmid ( Figure 6B  lane 6 ). This result suggests that even though LepB is not required for colicin E3 toxicity, the rate of the processing might be modulated by LepB, although no interaction between colicin E3 and LepB was detected by Far Western blotting ( Figure 3B lane 8) .
The same processed fragment was detected in vivo by either the "fishing" technique, using an ImmE3-6His protein expressed endogenously or directly from the cytoplasm ( Figure 6D , lane 2 compared to lane 3). The comparison confirms that the PF of colicin E3, which is trapped by ImmE3, corresponds mainly to the catalytic ribonuclease domain. This in vivo detected PF has a size close to 15 kDa, as deduced from comparison with the migration of a set of in vitro synthesized Cterminal peptides of colicin E3, overlapping the catalytic domain ( Figure 4B ). This allows us to estimate that the cleavage site generating PF is close to residue D420 of colicin E3 ( Figure 2B ). We note that the ColE3 PF is about 2 to 4 kDa heavier, than the SC forms detected after cleavage in vitro in the presence of OmpT ( Figure 4C ). In fact, the in vivo processing site of colicin E3 is located inside the C-terminal part of the central receptorbinding domain.
DISCUSSION
In the present work we have demonstrated, in the case of two different RNase colicins, that an endoproteolytic processing step is essential for their import into the cell and for subsequent cell killing. Using two distinct experimental protocols, we have shown for both colicins D and E3 that only their cytotoxic C-terminal, catalytic domains (12.4 kDa for colicin D or 15 kDa, for colicin E3) can be detected in the cytoplasm of cells exposed to the colicins. The same processed forms (PF) were detected in both sensitive or immunity-protein protected cells. The PFs found in the cytoplasm are significantly longer than the minimal size of the C-terminal domains required for catalytic activity. In the case of colicin D, the 18 additional amino acids (positions 590-607) present in the PF (Figure 2A ) were shown to be implicated in the interaction with the immunity protein (ImmD) and could also be required for tRNA target recognition (27). In the case of colicin E3, the 31 additional residues in the PF (positions D420-K450) ( Figure 2B) are derived from the 100 Å long hairpin structure of the receptor-binding (R) domain (38). This suggests that the R-domain should be partly unfolded to allow the RNase domain to reach the periplasmic side of the inner membrane. Such a conformational change of the R-domain may be compatible with its stable interaction with the receptor BtuB because this latter interaction only involves residues of the Rdomain near to the tip of the coiled coil structure (41). The partial unwinding of the termini of the coiled coil R domain (41, 42) facilitates both the insertion of the N-terminal part of the T-domain through OmpF and then the subsequent unfolding of the C-terminal part of colicin E3, thus allowing catalytic domain to reach the cytoplasmic membrane, so that it can enter the cytoplasm (Figure 7 ) (42). In agreement with a specific cascade of events during their import (depicted for both colicins in Figure 7 ), we show that the processing of colicins D and E3 does not occur, if their translocation across the outer membrane is prevented by mutations affecting their receptors (FepA or BtuB) or the energytransducer Ton or Tol system (Figures 5, 6) .
Our work has shown that the inner membrane, ATP-dependent and membraneanchored protease FtsH (43) is essential for the processing of both colicins D and E3 and/or the translocation of the processed form (PF) into the cytoplasm (Figure 7 ). In particular, we show that there is a strict correlation between the loss of sensitivity of ftsH mutants to nuclease colicins, as previously reported (26) , and the absence of PF in the cytoplasm of colicin-treated, FtsH-deficient cells. It was previously shown that sensitivity to nuclease colicins requires both the protease and ATPase activities of FtsH (26) . Our tentative conclusion is that the FtsH endopeptidase is the catalytic enzyme required for colicin processing.
The usual biological function of FtsH consists of the dislocation and degradation of misfolded or damaged membrane proteins (43) by "pulling" them into cytoplasm (44, 45). FtsH rather than unfolding the substrates itself, preferentially acts on already unfolded proteins (46, 47). The presence of an unstructured terminal tail of membrane substrates that penetrate into the cytoplasm appeared to be important to initiate the FtsH-dependent proteolysis (48). It is conceivable that DNase colicins have a similar access to FtsH because their nuclease domain exhibits an endogenous channel-forming activity, possibly allowing its self-propulsion into the cytoplasm (14, 15 ).
An electrostatically mediated interaction of the nuclease domain of E type colicins with the inner membrane has been reported (16) . This could lead to (or maintain) a partial unfolding of the catalytic domain, so that the unstructured C-terminal end may be recognized by FtsH as substrate (Figure 7) . FtsH-dependent ATP hydrolysis could contribute to the translocation of the RNase domain towards the proteolytic active site residing in the central pore of FtsH (49, 50).
The normal mode of action of FtsH is a processive proteolytic degradation, which liberates 10-26 residue oligopeptides into the cytoplasm (43). However the in vivo cleavage of RNase colicins D and E3 generates exceptionally long C-terminal peptides of 108 and 132 residues, respectively. This major difference compared to its usual substrates may be correlated with a particular degradation pathway shown in vitro for FtsH. After translocating an internal loop of a model substrate to the protease chamber, the proteolysis is initiated from an internal site. This liberates some discrete fragments of about 30 kDa and the proteolysis proceeds in the Ct to Nt direction processively (50, 51).
We previously isolated a mutation in the gene for the signal-peptidase lepB (N274K) (strain A38), which rendered the cell resistant to colicin D killing. We have now demonstrated that LepB plays a specific role in colicin D processing and translocation ( Figure  5 ). The analysis of two mutations in lepB proves that the function of LepB in colicin import is not enzymatic. The K145A LepB has no catalytic activity (35), but it still restores sensitivity to colicin D of the N274K lepB mutant strain and is able to interact in vitro with colicin D, almost as well as wild-type LepB (Figure 3 ). In contrast, strain A38 with the N274K lepB mutation showed no apparent deficiency with respect to the processing of normal LepB substrates (17) . In addition to the absence of any PF in the N274K lepB mutant strain, we also showed in vitro a large decrease in the interaction between the N274K LepB protein and the central domain of colicin D (Figure 3 ). Together these results are consistent with a structural role of LepB, which could interact with the central domain of colicin D and modify the structure of the tRNase domain so as to allow proteolysis by FtsH. Specific "adaptator proteins" have been shown to be required for recognition of other soluble protein substrates by FtsH (43).
An interesting question is why does colicin D processing require a specific interaction with LepB, but colicin E3 does not? Cytotoxicity of DNase colicins has been shown to depend upon the net positive charge of their DNase domain, essential for their interaction with the inner membrane (26) . Similarly, a productive interaction of the RNase domain of colicin E3 with the inner membrane could be ascribed to its high net positive charge (+11). In contrast, the weak positive charge of the tRNase domain of colicin D (+2) may be insufficient to allow an electrostatic interaction with the inner membrane. Thus, the interaction of colicin D with the membrane may be ensured or stabilised by a direct contact between its central domain and the LepB protein at the periplasmic side of the inner membrane ( Figure  7) .
It is striking that there are four parallel requirements for bacterial-toxin import into mammalian cells and nuclease-colicin import into E. coli (52, 53). Import into both the eukaryotic and prokaryotic systems necessitates: (i) Hijacking of a quality control system of protein folding; (ii) Endoproteolytic cleavage of the toxin during translocation; (iii) A chaperone protein to access the membrane translocator; and (iv) ATP hydrolysis.
In addition to colicin D, other nuclease colicins, e.g. the rRNase colicin E3 (Figure 4) , the DNase colicins E7 (18, 19) and E2 (25) and M. de Zamaroczy unpublished data) have been shown to be cleaved in vitro by periplasmic extracts and in all cases the in vitro cleavage was strictly dependent upon OmpT. In this work we have shown that the cleavage of colicins D and E3 by purified OmpT (or by periplasmic extracts) occurs at a different site from the authentic in vivo processing site we have mapped (Figure 2) . The OmpT-dependent colicin cleavages observed in vitro (Figures 1  and 4 ) appear to reflect the role of OmpT at the cell surface, as a part of the bacterial defense system to rid itself of extraneous and nefarious proteins (54). The degradation of colicin D by OmpT at the cell surface presumably requires the attachment of colicin-Imm complex to the FepA receptor ( Figure 7 ) and then is accelerated by the release of the immunity protein ( Figure 4 ). In contrast, we have clearly shown that OmpT cleavages are not involved in the import of colicins into target cells. Contrary to a previous hypothesis (19) , there is no evidence for periplasm-dependent processing during the import of nuclease colicins into the cytoplasm.
It is interesting to note however, that the productive in vivo processing of colicin D by FtsH and the in vitro observed cleavage by OmpT both require LepB. It is conceivable that these endoproteolytic cleavages of colicin D freed of its Imm protein require a similar folding of the C-terminal part of the colicin D molecule to allow access of FtsH or OmpT to their distinct, but rather closely located cleavage sites preceding the catalytic domain. The appropriate conformation of the Cterminal part of the colicin D for these cleavages seems to be mediated by the specific structural interaction of the colicin D central domain with LepB. ColE3-ImmE3) . The proteins of the S100 cytoplasmic fractions (S100 ompT (lanes 1-3 and 6, 7) or S100 tolB (lanes 4, 5)) were separated directly on 15% SDS-PAGE and analysed by Western blotting with anti-colicin E3 antiserum. The processed form (ColE3 PF) was revealed by ECL, quantified and expressed as a percentage of the value measured in LB (lane 6, 100 %). MW of reference proteins is given in kDa. Full-size colicin E3 is shown (FS ColE3 58 kDa) . B. Cells of FtsH-deficient (lanes 1, 2; S100 ftsH), btuB-inactivated (lanes 3, 4; S100 btuB), lepB-mutant (lane 5-7; S100 lepB-N274K) and carrying the pLEPB(wt) plasmid (lane 6; S100 lepB+pLEPB), and wild-type (lanes 8, 9; S100 wt) strains grown in LB medium were treated with ColE3-ImmE3 and analysed as described in (A). ColE3 PF was quantified as in (A) and expressed as a percentage of the value measured in S100 wt (lane 8, 100 %). C. Time course of the processing of colicin E3 performed in ompT-inactivated cells grown in minimal medium and treated with ColE3-ImmE3 for the times given (min). The amount of ColE3 PF in S100 ompT extracts was quantified and expressed as a percentage of the amount detected after 15 min (lane 4, 100 %). D. Comparison of the size of ColE3 PFs detected after treatment with ColE3-ImmE3, either by "fishing" (lane 2) in ompT-ImmE3(6H) strain grown in LB or by "direct" immuno detection (lane 3) from a S100 ompT cytoplasmic fraction. The ImmE3 protein, (lanes 1, 2 and boxed) was revealed by immuno detection with an anti-6His-tag antiserum, performed separately with the bottom part of the same blot. (58)). 3. The processing and translocation mechanisms of both RNase colicins are unknown, but require an active FtsH (ATPase/protease) to allow the processed forms (PF) to reach the cytoplasm. 4. The nucleases imported by PFs cleave either 16S rRNA (colicin E3) or tRNAs Arg (colicin D) preventing protein synthesis (1, 2) and so, lead to target cell death. 
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